Department

Women's Health

Pelvic radiation injury (FDA), endometriosis (investigational)

1 FDA-approved 1 research

HBOT Applications

FDA-Approved Level A

Pelvic Radiation Injury

HBOT for late radiation tissue injury in pelvic structures (radiation cystitis, proctitis, vaginal stenosis) following gynaecological cancer radiotherapy. Cross-references the FDA-approved Delayed Radiation Injury indication; the women's-health context emphasises pelvic-specific manifestations.

Protocol

Pressure

2.0 – 2.4 ATA

Duration

90 min

Sessions

30 – 60

Frequency

Once daily, 5×/week

Evidence basis: UHMS / Standard of Care

References: 1 12
Emerging Evidence Level C

Endometriosis

Investigational application supported by translational evidence in rodent models and one registered randomised trial (HEROES, NCT06579040) currently recruiting. No published human clinical evidence yet; HBOT is positioned as an investigational adjunct, not standard of care.

Protocol

Pressure

Not standardised

Duration

Not standardised

Sessions

Not standardised (HEROES trial protocol pending publication)

Frequency

Not standardised

Evidence basis: Translational + Registered Trial Awaiting Results

References: 41 42 43